Floatz logo

Dc-Cik

Survival

China Meitan General HospitalCell therapyPhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

0 Active assets in the Survival cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
China Meitan General Hospital
Phase 4BB
Calcium folinate pentahydrate
China Meitan General Hospital
Phase 4BB
Capecitabine
National Cancer Institute, Egypt
Phase 2B

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →